Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase

Cancer Research

Volumn 62, Issue 6, 2002, Pages 1707-1717

  Matranga, Christian B ^a   Shapiro, Geoffrey I ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE; FLAVOPIRIDOL; GEMCITABINE; HYDROXYUREA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELL SYNCHRONIZATION; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SENSITIZATION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRONCHI; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TRANSFORMED; CISPLATIN; CYCLIN-DEPENDENT KINASES; DEOXYCYTIDINE; DNA; DNA, NEOPLASM; DRUG INTERACTIONS; ENZYME INHIBITORS; EPITHELIAL CELLS; FIBROBLASTS; FLAVONOIDS; HUMANS; LUNG NEOPLASMS; PIPERIDINES; S PHASE; TUMOR CELLS, CULTURED;

EID: 0037086282     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. A family of human cdc2-related protein kinases
2. 1 phase progression: Cycling on cue
3. Cyclins: Wheels within wheels
4. 1-phase progression
5. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer
6. Cancer cell cycles
7. Anticancer drug targets: Cell cycle and checkpoint control
8. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
9. 1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells
10. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
11. Down-regulation of cyclin Dl by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
12. Preclinical and clinical development of cyclin-dependent kinase modulators
13. Cyclin-dependent kinase inhibitors: Novel anticancer agents
14. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status
15. Small molecule inhibitors of cyclin-dependent kinases
16. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines
17. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
18. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
19. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes
20. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol
21. Flavopiridol binds to duplex DNA
22. Cytotoxic synergy between flavopiridol and various antineoplastic agents: The importance of sequence of administration
23. Potentiation of apoptosis by flavopiridol in mitomycin C-treated gastric and breast cancer cells
24. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in HCT 116 colon cancer monolayers and xenografts
25. Kipl
26. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
27. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 activity
28. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
29. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
30. Cell cycle-independent induction of apoptosis by the antitumor drug flavopiridol in endothelial cells
31. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase
32. Differential regulation of E2F transactivation by cyclin-cdk2 complexes
33. Cyclin A/Cdk2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation
34. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
35. 1-S transition and S-phase progression
36. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human in the human KB cancer cell line
37. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of the ribonucleotide reductase M2 subunit
38. Gemcitabine in leukemia: A Phase I clinical, plasma, and cellular pharmacology study
39. Distinct roles for cyclin-dependent kinases in cell cycle control